Surgery in patients with haemophilia and high responding inhibitors: Izmir experience

Haemophilia

Volumn 16, Issue 6, 2010, Pages 902-909

  Balkan, Can ^a   Karapinar, D ^a   Aydogdu, S ^a   Ozcan, C ^a   Ay, Y ^a   Akin, M ^a   Kavakli, K ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

APCC; Haemophilia A; Haemostasis; Inhi bitor; RFVIIa; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING INHIBITOR; FIBRIN GLUE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BRAIN SURGERY; BRAIN VENTRICLE PERITONEUM SHUNT; CHILD; CIRCUMCISION; CLINICAL ARTICLE; DRUG EFFICACY; ESOPHAGUS DILATATION; HEMOPHILIA; HEMOSTASIS; HUMAN; MAJOR SURGERY; MINOR SURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SYNOVECTOMY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; FACTOR VIIA; HEMOPHILIA A; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TURKEY; YOUNG ADULT;

EID: 78049311744     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02329.x     Document Type: Article

References (38)

1. Lloyd JM, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
2. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Eng J Med 1980; 303: 421-5.
3. Syamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double blind clinical trial. N Eng J Med 1981; 305: 717-21.
4. Hilgartner M, Knatterud GL, the FEIBA study group. The use of factor VIII by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitor. Blood 1983; 61: 36-40.
5. Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe hemophilia A during synovectomy. Lancet 1988; 2: 1193.
6. Rao L, Rapaport SI. Cells and the activation of factor VII. Haemostasis 1996; 26: 1-5.
7. Quintana-Molina M, Martinez-Bahamonde F, Gonzales-Garcia E et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004; 10: 30-40.
8. Lauroua P, Ferrer AM, Guerin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia 2009; 15: 1300-7.
9. Gringeri A, Mantovani LG, Scalone L, Manucci PM, for the COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
10. Fernandez-Palazzi F, Caviglia H. On the safety of synoviorthesis in hemophilia. Haemophilia 2001; 7: 50-3.
11. Kavakli K, Aydogdu S, Omay SB et al. Long-term evaluation of radioisotope synovectomy with Yttrium 90 for chronic synovitis in Turkish haemophiliacs: Izmir experience. Haemophilia 2006; 12: 28-35.
12. Kavakli K, Aydogdu S, Taner M et al. Radioisotope synovectomy with rhenium 186 in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia 2008; 14: 518-23.
13. Avanoglu A, Çelik A, Ulman I et al. Safer circumcision in patients with haemophilia: the use of fibrin glue for local haemostasis. BJU int 1999; 83: 91-4.
14. Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10: 22-9.
15. White B, Smith OP. General and emergency surgery in patients with high-responding inhibitors. Chapter 28. In: Rodriguez-Merchan EC, Lee CA eds. Inhibitors in Patients with Haemophilia. Oxford: Blackwell Publishing, 2002: 179-82.
16. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-31.
17. Astermark J, Rocino A, Von Depka M et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.
18. Hilgartner M, Aledort L, Andres A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
19. Negrier C, Goudemand J, Sultan Y et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 113-9.
20. Tjonnfjord GE, Brinch L, Gedde-Dahl III, Brosstad FR. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
21. Bollard CM, Teague LR, Berry EN, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000; 6: 66-70.
22. Morado M, Jimenez-Yuste V, Villar A et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001; 7: 551-6.
23. Rodriguez-Merchan EC, Rocino A, Ewnstein B et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 2004; 10: 50-2.
24. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10 year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
25. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14: 39-43.
26. Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26: 118-23.
27. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinol 1998; 9: 119-28.
28. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or factor IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
29. DiMichele D. The use of recombinant factor VIIa (NovoSeven) for central catheter insertion: an international experience. Thromb Haemost 1997; 77: 167-72.
30. Shapiro AD, Gilchrist GS, Hoots WK et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
31. Kenet G, Lubetzky A, Luboshitz J. Treatment of inhibitor patients with rFVIIa: continuous infusion protocols as compared to a single dose. Haemophilia 2000; 76: 297. [Abstract].
32. Laguna P, Klukowska A. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor. Haemophilia 2005; 11: 2-4.
33. Hvas Am, Sorensen HT, Norengaard L et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
34. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
35. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002; 88: 60-5.
36. Rosenfeld SB, Watkinson KK, Thompson BH, Macfarlane DE, Lentz SR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002; 87: 925-6.
37. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
38. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.